tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Nov 20;90:107220.
doi: 10.1016/j.intimp.2020.107220. Online ahead of print.
COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus
Camila B P da Costa[SUP] 1 [/SUP], Francislene J Martins[SUP] 2 [/SUP], Luis E R da Cunha[SUP] 3 [/SUP], Norman A Ratcliffe[SUP] 4 [/SUP], Rafael Cisne de Paula[SUP] 5 [/SUP], Helena C Castro[SUP] 6 [/SUP]
Affiliations
Abstract
Since the very beginning of the COVID-19 pandemic, different treatment strategies have been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti-inflammatory agents as well as vaccine production. However, other potential options should be more avidly investigated since vaccine production on a worldwide level, and the anti-vaccination movement, also known as anti-vax or vaccine hesitancy by many communities, are still real obstacles without a ready solution. This review presents recent findings on the potential therapeutic advantages of heterologous serotherapy for the treatment of COVID-19. We present not only the effective use in animal models of hyperimmune sera against this coronavirus but also strategies, and protocols for the production of anti-SARS-CoV-2 sera. Promising antigens are also indicated such as the receptor-binding domain (RBD) in SARS-CoV-2 S protein, which is already in phase 2/3 clinical trial, and the trimeric protein S, which was shown to be up to 150 times more potent than the serum from convalescent donors. Due to the high death rate, the treatment for those currently infected with coronavirus cannot be ignored. Therefore, the potential use of anti-SARS-CoV-2 hyperimmune sera should be carefully but urgently evaluated in phase 2/3 clinical studies.
Keywords: Animal antibodies; COVID-19; Coronavirus; Hyperimmune sera; Neutralizing titers; SARS-COV-2.
. 2020 Nov 20;90:107220.
doi: 10.1016/j.intimp.2020.107220. Online ahead of print.
COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus
Camila B P da Costa[SUP] 1 [/SUP], Francislene J Martins[SUP] 2 [/SUP], Luis E R da Cunha[SUP] 3 [/SUP], Norman A Ratcliffe[SUP] 4 [/SUP], Rafael Cisne de Paula[SUP] 5 [/SUP], Helena C Castro[SUP] 6 [/SUP]
Affiliations
- PMID: 33302034
- PMCID: PMC7678452
- DOI: 10.1016/j.intimp.2020.107220
Abstract
Since the very beginning of the COVID-19 pandemic, different treatment strategies have been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti-inflammatory agents as well as vaccine production. However, other potential options should be more avidly investigated since vaccine production on a worldwide level, and the anti-vaccination movement, also known as anti-vax or vaccine hesitancy by many communities, are still real obstacles without a ready solution. This review presents recent findings on the potential therapeutic advantages of heterologous serotherapy for the treatment of COVID-19. We present not only the effective use in animal models of hyperimmune sera against this coronavirus but also strategies, and protocols for the production of anti-SARS-CoV-2 sera. Promising antigens are also indicated such as the receptor-binding domain (RBD) in SARS-CoV-2 S protein, which is already in phase 2/3 clinical trial, and the trimeric protein S, which was shown to be up to 150 times more potent than the serum from convalescent donors. Due to the high death rate, the treatment for those currently infected with coronavirus cannot be ignored. Therefore, the potential use of anti-SARS-CoV-2 hyperimmune sera should be carefully but urgently evaluated in phase 2/3 clinical studies.
Keywords: Animal antibodies; COVID-19; Coronavirus; Hyperimmune sera; Neutralizing titers; SARS-COV-2.